Affiliation:
1. Molecular Pharmacology Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan 20133, Italy
Abstract
Prostate cancer is the fifth cause of tumor-related deaths in man worldwide.
Due to its long latency period, this pathology represents an ideal type of disease for chemopreventive
studies. Among the drugs considered thus far for the treatment of prostate
cancer, the natural compound resveratrol emerged as very promising. Resveratrol is widely
recognized as a chemopreventive agent and was shown to potentiate the antitumor activity
of conventional chemotherapeutics in several tumors, including prostate cancer.
Here, we overview the literature of the last five years and summarize the recent achievements
of resveratrol and its derivatives as antimetastatic agents in prostate cancer. Moreover,
drug combination studies as well as nanomedicine approaches proposed to improve
resveratrol activity and to overcome delivery drawbacks are addressed. The last part of
the review discusses the clinical trials containing resveratrol ongoing on cancer patients.
Publisher
Bentham Science Publishers Ltd.
Subject
Pharmacology,Molecular Medicine,Drug Discovery,Biochemistry,Organic Chemistry
Cited by
29 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献